Study of Dasatinib in Patients With Advanced Solid Tumors

• Status: Terminated
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of Segment 1 of the study is to determine the effect of ketoconazole on dasatinib. The purpose of Segment 2 is to learn how dasatinib affects tumor growth in patients with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Dasatinib; Ketoconazole

Criteria

Inclusion Criteria:

• ECOG status 0-2

• Advanced or metastatic disease, unresponsive to standard treatment (or no standard treatment exists)

• Biopsy pretreatment

• Adequate bone marrow, liver and kidney function

Exclusion Criteria:

• Serious cardiovascular disease

• Bleeding disorders

• Gastrointestinal (GI) tract disease

• Platelet inhibitors

• H2 blockers, proton pump inhibitors